This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
DigitalHealth Technologies ( DHTs ) have revolutionized the landscape of clinical trials, particularly in neurology research, by enabling the collection of real-world data outside traditional clinical settings.
BASEL, Switzerland–(BUSINESS WIRE)–Indivi, a leading MedTech company headquartered in Basel, Switzerland, has entered into an agreement with Biogen to advance digitalhealth technology and developdigital biomarkers for Parkinson’s disease.
Healthcare stakeholders such as health systems, pharmaceutical companies, biotech and life sciences firms, and insurance companies serve patients as end users. Market forces drove acceleration in digitalhealth, specifically telemedicine, which were sorely needed for several years. Connect with her at [link].
This pilot study represents a critical step in leveraging digitalhealth technology to enhance cancer treatment outcomes,” said John Wagner, M.D., The study, led by principal investigator Nitin Ohri, M.D., Chief Medical Officer, Koneksa. “By
QuantHealth bridges these gaps by simulating trials at scale, to expedite, derisk, and optimize drugdevelopment. QuantHealth proudly supports several large pharma companies, numerous biotechs, as well as CROs, and other industry partners.
Koneksa’s digital biomarker solutions include an industry-leading platform that gives research sponsors and clinical sites the ability to seamlessly aggregate data in real-time from devices, ePROs, patient diaries, and clinical assessments to provide the full picture of an individual’s health.
–(BUSINESS WIRE)–AstraZeneca today launches Evinova, set to be a leading provider of digitalhealth solutions to better meet the needs of healthcare professionals, regulators and patients.
The utilization of evidence-based digital biomarkers is the key to transforming healthcare,” said Chris Benko, CEO, Koneksa. “We’re We’re on a mission to revolutionize drugdevelopment in clinical trials by harnessing the power of our digital solutions with real-time, data-driven insights.
These individuals have personally built leading technology platforms supercharging drugdevelopment globally. Their buy-in shows that our platform is differentiated and poised to unlock truly novel therapies for currently underserved patient populations through efficient, simulation-guided development. Jane Rhodes, Ph.D.,
23andMe tried to monetize its extensive genetic database by collaborating with pharmaceutical companies for drug research. While promising, drugdevelopment requires significant time and investment, delaying any financial returns and impacting the company’s short-term revenue.
Founded in 2018 and supported from the outset by LallianSe, the life sciences integrator, BrainTale has developed and commercializes an accessible, reliable and clinically validated brain measurement digital platform solution for drugdevelopers and physicians – neurologists, neuroradiologists and intensivists.
–(BUSINESS WIRE)– Aviceda Therapeutics , a clinical-stage biotech company focused on developing next-generation immuno-modulators to treat diseases such as cancer, today announced a strategic partnership with the Patrick G Johnston Centre for Cancer Research at Queen’s University Belfast (Queen’s). CAMBRIDGE, Mass.–(BUSINESS
About Automera Automera is an early-stage company focused on the development of a novel therapeutic approach via autophagy-based targeted protein degradation. ClavystBio was conceived and launched by Temasek to be a venture builder, trusted partner, and keystone to catalyze global health solutions from Singapore.
Their expertise in company building, capital formation, and drugdevelopment will be a tremendous resource to Avilar as the innovation leader in the new field of extracellular protein degradation.” Find out more: www.sanofiventures.com.
Here are some key trends and developments to watch: Key Trends: Technological Advancements: New technologies are revolutionizing wound care, including advanced wound dressings, bioengineered skin substitutes, and innovative wound management devices. This shift towards digitalisation is improving patient outcomes and reducing healthcare costs.
We aim to bring together relevant stakeholders, including payers, providers, patients groups, and biotech and when and where needed we cooperate with pharma, to be the one voice of the industry. The pipeline for new antibiotics is limited, which is partly due to how new drugdevelopment is funded.
Both Wellington and Forbion are visionaries and highly experienced biotech investors, and we look forward to working closely with them in our efforts to transform the gene editing landscape.” “Our billion across multiple fund strategies that cover all stages of (bio-) pharmaceutical drugdevelopment.
We organize all of the trending information in your field so you don't have to. Join 48,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content